search
Back to results

Lactate Therapy After Traumatic Brain Injury (LS_TCC)

Primary Purpose

Traumatic Brain Injury, Subarachnoid Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
sodium lactate infusion
Sponsored by
Centre Hospitalier Universitaire Vaudois
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic Brain Injury focused on measuring traumatic brain injury, lactate, brain metabolism, cerebral microdialysis, subarachnoid hemorrhage, transcranial doppler

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients admitted to our intensive care unit (ICU) after severe TBI or poor-grade aneurysmal subarachnoid hemorrhage (SAH), defined by a post-resuscitation Glasgow Coma Scale (GCS) < 9
  • Age 18-75 years
  • Abnormal head CT-scan (Marshall grade ≥ 2 or Fisher >2)
  • Intracranial pressure (ICP), PbtO2 and cerebral MD monitoring as part of standard care

Exclusion Criteria:

  • Penetrating TBI
  • non aneurysmal SAH
  • Age < 18 or > 75 years,
  • More than 1 extra-cranial injury with sustained hemodynamic instability and sustained blood lactate elevation > 4 mmol/L
  • Cognitive handicap due to previous neurological or neurosurgical history
  • Non-survivable injury, brain death or expected death within 48 hours
  • Pregnancy

Sites / Locations

  • CHUV, Lausanne University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

sodium lactate infusion

Arm Description

Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours

Outcomes

Primary Outcome Measures

Increase from baseline in brain extracellular lactate, pyruvate and glucose
Increase from baseline in brain extracellular lactate, pyruvate and glucose measured with intra-parenchymal cerebral microdialysis catheter

Secondary Outcome Measures

Increase from baseline in brain tissue PO2
Brain tissue PO2 will be measured with intra-parenchymal probes
Increase from baseline in cerebral perfusion pressure
Decrease from baseline in intracranial pressure
plasma sodium
plasma osmolality
mean CBF, measured by transcranial doppler

Full Information

First Posted
April 1, 2012
Last Updated
September 8, 2021
Sponsor
Centre Hospitalier Universitaire Vaudois
Collaborators
Swiss National Science Foundation, European Society of Intensive Care Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01573507
Brief Title
Lactate Therapy After Traumatic Brain Injury
Acronym
LS_TCC
Official Title
Neuroprotective Role of Lactate Therapy in Humans With Traumatic Brain Injury
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
March 2012 (Actual)
Primary Completion Date
December 18, 2017 (Actual)
Study Completion Date
December 18, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre Hospitalier Universitaire Vaudois
Collaborators
Swiss National Science Foundation, European Society of Intensive Care Medicine

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: Although glucose is essential to cerebral function, abundant experimental and clinical evidence demonstrates that endogenously released lactate, rather than glucose, is the preferential energy substrate for the brain in conditions of stress and acute injury. In patients with severe Traumatic Brain Injury (TBI) and aneurysmal subarachnoid hemorrhage (SAH) monitored with cerebral microdialysis and brain tissue oxygen (PbtO2), our preliminary data show that increased brain extracellular lactate is frequently observed. Our findings indicate that elevated brain lactate more often occurs in the absence of brain hypoxia/ischemia and is mainly the consequence of increased cerebral glycolysis, i.e. it occurs in association with high extracellular pyruvate. These data suggest that the primary source of elevated lactate is activated glycolysis and strongly support the concept that endogenously released lactate can be utilized by the injured human brain as energy substrate. They prompt further investigation to examine whether exogenous lactate supplementation can be a valuable neuroprotective strategy after TBI or SAH. Indeed, in animal models of brain injury, administration of exogenous lactate improves neuronal and cognitive recovery. Hypothesis: The investigators test the hypothesis that lactate therapy, administered during the acute phase of TBI or SAH, might exercise neuroprotective actions by restoring brain energetics and improving brain tissue PO2 and cerebral blood flow (CBF). Aim of the study: The aim of this single-center study is to examine the effect of sodium lactate infusion on cerebral extracellular metabolites, brain tissue PO2 and cerebral blood flow, measured with CT perfusion and transcranial doppler (TCD). Design: Prospective phase II interventional study examining the effect of a continuous 3-6 hours infusion of sodium lactate (20-40 µmol/kg/min), administered within 48 hours from TBI or SAH, on cerebral extracellular glucose, pyruvate, glutamate, glycerol, PbtO2 and CBF.
Detailed Description
Study: Prospective, single-centre phase II interventional study. The study will take place at the Department of Intensive Care Medicine, Lausanne University Medical Center (Centre Hospitalier Universitaire Vaudois, CHUV), Lausanne, Switzerland. Patient population: Patients will be monitored with an intra-parenchymal monitoring system, consisting of ICP (Codman®, Integra Neurosciences), PbtO2 (Licox®, Integra Neurosciences) and cerebral microdialysis (CMA Microdialysis®) catheters, based on the protocol for management of TBI presently in use at our center. Each patient will receive a continuous infusion of sodium lactate (composition: lactate 1'000 mmol/L, Na 1'000 mmol/L: concentration 20-40 µmol/kg/min) for 3-6 hours. Sodium lactate will be prepared locally by the Pharmacie Centrale, CHUV, Lausanne. Each patient will serve as his/her internal control, and the effect of sodium lactate on all brain physiological variables measured will be anayzed before, during and at the end of sodium lactate infusion. The main parameters of efficacy are increases of MD glucose, MD pyruvate, PbtO2, and CBF, during sodium lactate perfusion. For both MD glucose and MD pyruvate, we fixed as the minimal detectable effect of sodium lactate infusion a 30% increase of glucose and pyruvate at the end of the study. To obtain a power of 0.8 with an alpha of 0.05, the number of patients required to complete the study is 33. We therefore plan to include 35 patients. Statistical analysis: At each time-point (baseline, during perfusion, end of sodium lactate infusion), differences of mean MD glucose, lactate, pyruvate, PbtO2, CBF, Mean transit time, ICP, CPP will be analyzed. We will also examine the percentage time spent with abnormal values (MD glucose < 1 mmol/L, PbtO2 < 20 mm Hg, ICP > 20 mm Hg). Differences will be compared using ANOVA for repeated measures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury, Subarachnoid Hemorrhage
Keywords
traumatic brain injury, lactate, brain metabolism, cerebral microdialysis, subarachnoid hemorrhage, transcranial doppler

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Hypertonic lactate
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
sodium lactate infusion
Arm Type
Experimental
Arm Description
Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
Intervention Type
Other
Intervention Name(s)
sodium lactate infusion
Intervention Description
3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
Primary Outcome Measure Information:
Title
Increase from baseline in brain extracellular lactate, pyruvate and glucose
Description
Increase from baseline in brain extracellular lactate, pyruvate and glucose measured with intra-parenchymal cerebral microdialysis catheter
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Increase from baseline in brain tissue PO2
Description
Brain tissue PO2 will be measured with intra-parenchymal probes
Time Frame
6 hours
Title
Increase from baseline in cerebral perfusion pressure
Time Frame
6 hours
Title
Decrease from baseline in intracranial pressure
Time Frame
6 hours
Title
plasma sodium
Time Frame
6 hours
Title
plasma osmolality
Time Frame
6 hours
Title
mean CBF, measured by transcranial doppler
Time Frame
6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients admitted to our intensive care unit (ICU) after severe TBI or poor-grade aneurysmal subarachnoid hemorrhage (SAH), defined by a post-resuscitation Glasgow Coma Scale (GCS) < 9 Age 18-75 years Abnormal head CT-scan (Marshall grade ≥ 2 or Fisher >2) Intracranial pressure (ICP), PbtO2 and cerebral MD monitoring as part of standard care Exclusion Criteria: Penetrating TBI non aneurysmal SAH Age < 18 or > 75 years, More than 1 extra-cranial injury with sustained hemodynamic instability and sustained blood lactate elevation > 4 mmol/L Cognitive handicap due to previous neurological or neurosurgical history Non-survivable injury, brain death or expected death within 48 hours Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mauro Oddo, MD
Organizational Affiliation
CHUV, Lausanne University Hospital, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHUV, Lausanne University Hospital
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29923931
Citation
Carteron L, Solari D, Patet C, Quintard H, Miroz JP, Bloch J, Daniel RT, Hirt L, Eckert P, Magistretti PJ, Oddo M. Hypertonic Lactate to Improve Cerebral Perfusion and Glucose Availability After Acute Brain Injury. Crit Care Med. 2018 Oct;46(10):1649-1655. doi: 10.1097/CCM.0000000000003274.
Results Reference
derived
PubMed Identifier
24477453
Citation
Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, Bloch J, Messerer M, Levivier M, Meuli R, Magistretti PJ, Oddo M. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014 Mar;40(3):412-21. doi: 10.1007/s00134-013-3203-6. Epub 2014 Jan 30.
Results Reference
derived

Learn more about this trial

Lactate Therapy After Traumatic Brain Injury

We'll reach out to this number within 24 hrs